West Pharmaceutical Services, Inc. WST
Regular-session close
After hours · Nov 20, 6:16 PM ET
- YTD
- +41.86%
- 1 year
- +51.41%
5D -26.81 (-6.43%)
- Market cap
- 27.19B
- Revenue (ttm)
- 3.40B
- Profit margin
- 18.81%
- EPS (ttm)
- 8.91
- Shares out
- 69.66M
- P/E ratio
- 43.80
- Forward P/E
- 37.58
- Dividend
- 1.04 (0.26%)
- Ex-dividend date
- Nov 10, 2026
- YTD return
- +41.86%
- 1-year return
- +51.41%
- Volume
- 623.50K
- Avg volume
- 617.30K
- Open
- 387.71
- Previous close
- 396.69
- Day's range
- 389.75 – 400.90
- 52-week range
- 230.95 – 417.80
- Beta
- 1.14
- Analysts
- Strong Buy
- Price target
- 471.00 (+20.7%)
- Earnings date
- Feb 11, 2027
- 50-day average
- 385.65
Key statistics
- 200-day average
- 324.87
- Enterprise value
- 27.48B
- PEG ratio
- 2.94
- Price / sales
- 8.01
- Price / book
- 9.18
- Payout ratio
- 9.88%
- Revenue growth
- 8.70%
- Free cash flow
- 345.56M
- Total cash
- 464.10M
- Total debt
- 313.90M
- Return on equity
- 21.23%
- Short % of float
- 3.04%
Fundamental scorecard
20 of 25 checks passed on WST’s reported financials
20of 25 checks passed
- Value 2 of 5
- Growth 5 of 5
- Profitability 4 of 5
- Financial health 5 of 5
- Dividend 4 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 340.00
- Target (mean)
- 471.00
- Target (high)
- 500.00
- Strong buy3
- Buy12
- Hold0
- Sell0
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 2.28.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 2.27 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.20 | 2.66 | +0.46 | +20.91% |
| Jul 23, 2026 | Jun 30, 2026 | 2.08 | 2.37 | +0.29 | +13.94% |
| Apr 23, 2026 | Mar 31, 2026 | 1.68 | 2.13 | +0.45 | +26.79% |
| Feb 12, 2026 | Dec 31, 2025 | 1.83 | 2.04 | +0.21 | +11.48% |
| Oct 23, 2025 | Sep 30, 2025 | 1.68 | 1.96 | +0.28 | +16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Citigroup | main | Buy | Buy |
| Oct 30, 2026 | TD Cowen | main | Buy | Buy |
| Oct 30, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- westpharma.com
News
My Top Dividend Growth Picks In Each GICS Sector (November 2026)
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical Services, Inc. (WST) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
West Pharmaceutical Services, Inc. $WST Position Increased by Eurizon Capital SGR S.p.A. Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480
West Pharmaceutical Servs Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on WST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIRKETT BERNARD JOHN | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 17, 2025 | 7,520 |
| BUTHMAN MARK A | Director | Stock Award(Grant) | May 3, 2026 | 44,308 |
| FAVORITE ANNETTE F | Officer | Conversion of Exercise of derivative security | Sep 14, 2026 | 21,817 |
| FEEHERY WILLIAM F. | Director | Stock Award(Grant) | May 3, 2026 | 32,519 |
| GREEN ERIC MARK | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 175,418 |
| HOFMANN THOMAS W | Director | Stock Award(Grant) | May 5, 2025 | 44,637 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.62% | 6,702,494 | 2.62B | Sep 29, 2026 |
| FMR, LLC | 8.60% | 5,988,538 | 2.34B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.61% | 4,605,822 | 1.80B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.93% | 4,130,135 | 1.61B | Sep 29, 2026 |
| State Street Corporation | 4.78% | 3,329,438 | 1.30B | Sep 29, 2026 |
| Artisan Partners Limited Partnership | 2.88% | 2,007,802 | 784.18M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.22% | 2,242,860 | 875.98M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.63% | 1,830,358 | 714.87M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.20% | 1,530,738 | 597.85M | Jun 29, 2026 |
| Fidelity Contrafund | 1.87% | 1,299,716 | 507.62M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Growth Index Fund | 1.35% | 940,525 | 367.34M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.35% | 937,921 | 366.32M | Sep 29, 2026 |
